Forte Biosciences FBRX Income Statement (2016-2026)

NASDAQ FBRX
$76.99 +0.00 (+0.00%)
At close: Aug 28, 2026 · 4:00 PM EDT
Reported Financials

Forte Biosciences Quarterly Income Statement

Periods 42 quarters
Latest Jun 2026

Forte Biosciences reported net income of -$23.33M for the quarter ended Jun 2026. This income statement covers 42 quarters of results from Mar 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
Operating items
Research & DevelopmentR&D
5.66M1.35M0.69M1.03M1.38M2.49M4.79M7.14M6.37M3.57M4.32M5.59M5.72M5.08M12.54M8.47M15.05M21.59M20.32M22.19M
Selling, General & AdministrativeSG&A
2.04M1.95M1.82M1.99M2.04M2.45M2.07M1.90M3.85M2.81M3.45M7.08M2.76M2.12M3.43M2.96M3.18M2.83M1.97M2.27M
Other Operating ExpensesOther Opex
0.03M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M
Operating ExpensesOpex
7.70M3.30M2.51M3.02M3.42M4.94M6.86M9.03M10.22M6.38M7.80M12.82M8.63M7.35M16.12M11.58M18.38M24.57M22.44M24.60M
Operating IncomeOp. Inc
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
EBIT
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
Non-operating items
Non Operating Interest Expenses
Non Operating Investment IncomeNon-Op. Investment Inc.
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
-0.05M-0.04M-0.05M-0.01M0.02M-0.10M0.10M0.14M0.26M-0.61M0.38M0.31M0.24M-1.12M0.47M0.33M0.70M-1.90M0.68M1.47M
Non Operating IncomeNon Op. Inc.
Net income details
EBT
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-15.66M-11.25M-18.38M-24.57M-21.76M-23.14M
Tax ProvisionsTaxes
0.37M0.19M
Profit After TaxPAT
-7.75M-3.34M-2.57M-3.04M-3.40M-4.88M-6.75M-8.90M-9.96M-5.87M-7.42M-12.51M-8.39M-7.15M-15.66M-11.25M-17.69M-24.77M-22.14M-23.33M
Income from Continuing OperationsIncome (Continuing)
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-15.66M-11.25M-18.38M-24.57M-22.14M-23.33M
Consolidated Net IncomeConsol Net Inc.
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-15.66M-11.25M-18.38M-24.57M-22.14M-23.33M
Income towards Parent CompanyParent Net Inc
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-15.66M-11.25M-18.38M-24.57M-22.14M-23.33M
Net Income towards Common StockholdersNet Income
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-15.66M-11.25M-18.38M-24.57M-22.14M-23.33M
Additional items
EPS (Basic)
-13.52-5.90-4.26-5.11-4.52-7.10-8.16-10.73-6.75-5.05-4.23-6.95-4.67-2.52-1.37-0.96-1.03-1.67-1.24-0.98
EPS (Diluted)
-13.52-5.90-4.26-5.11-4.52-7.10-8.16-10.73-6.75-5.05-4.23-6.95-4.67-2.52-1.37-0.96-1.03-1.67-1.24-0.98
Shares Outstanding
0.57M0.56M0.59M0.59M0.76M0.70M0.84M0.84M1.51M1.26M1.84M1.85M1.85M2.92M11.40M11.74M17.79M14.72M17.84M23.79M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.57M0.56M0.59M0.59M0.76M0.70M0.84M0.84M1.51M1.26M1.84M1.85M1.85M2.92M11.40M11.74M17.79M14.72M17.84M23.79M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.59M0.59M0.59M0.59M0.84M0.70M0.84M0.84M1.45M1.45M1.84M1.85M1.85M2.92M11.40M12.28M17.79M12.95M17.84M20.48M
EBITDA
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
Interest ExpensesInt Expense
Tax Rate
-1.71%-0.83%